Authors

Dale R. Shepard, MD, PhD, FACP, Taussig Cancer Institute, Cleveland Clinic

Latest:

Dr. Laber on the PRODIGE 35-PANOPTIMOX Trial in Metastatic Pancreatic Cancer

Damian Laber, MD, hematologist/oncologist, senior member, Moffitt Cancer Center, discusses the PRODIGE 35-PANOPTIMOX trial in metastatic pancreatic cancer.

Damon Reed, MD, Moffitt Cancer Center

Latest:

Dr Reed on the Investigation of Trastuzumab Deruxtecan in HER2+ Osteosarcoma

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Dan Beachler,MD

Latest:

Dr. Beachler on HPV Vaccine Efficacy Among Previously Exposed Individuals

Dan Beachler, MD, fellow at the National Cancer Institute, discusses the efficacy of the HPV vaccine on individuals who have been previously exposed to the virus compared to those who have not.

Latest:

Specialty Pharmacy: Build, Buy, or Partner

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dan George, MD, Duke Cancer Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Daniel J. George, MD, Duke Cancer Institute

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment

Dan J. Raz, MD

Latest:

Dr. Raz on the Effects of COVID-19 on Lung Cancer Screening

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Dan Klein

Latest:

Payment Assistance for Patients With Cancer

Dan Klein, President and CEO of Patient Access Network Foundation, discusses payment assistance for patients with cancer.

Dan Pollyea, MD, MS, University of Colorado Cancer Center

Dan Theodorescu, MD, PhD

Latest:

Can New Technologies Be Used to Predict Treatment Response in Cancer Patients?

The next leap forward in cancer treatment will see physicians tailoring treatments based on patients' individualized tumor profiles.

Dan Zandberg, MD

Latest:

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dana Chase, MD

Latest:

Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Dana Chase, MD, FACOG

Latest:

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Dana E. Rathkopf, MD

Latest:

Dr. Rathkopf on AR-V7 Biomarker in Prostate Cancer

Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

Dana H. Felthouse, MBA

Latest:

Mission Possible: Managing Specialty Pharmacy Costs and Utilization

To get the right drug in the right amount at the right time to the patient in the most cost-effective manner